Needham Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $28
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.
Needham analyst Serge Belanger initiates coverage on Evommune (NYSE:EVMN) with a Buy rating and announces Price Target of $28.